Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants with Primary IgA Nephropathy in Combination with Stable Background Therapy'. The following are the other relevant details related to the trial:
Therapeutic Area: Renal Medicine
Trial Centre(s):
National University Hospital
Singapore General Hospital
Tan Tock Seng Hospital
Trial Status: Ongoing, Recruiting
Not Yet Recruiting
Principal Investigator(s):
Dr Jimmy Teo Boon Wee
Dr Jason Choo Chon Jun
Dr Yeo See Cheng
Published by HT Digital Content Services with permission from Health Dail...